Pilot Study of the Efficacy and Safety of CD38 Targeted Chimeric Antigen Receptor Engineered T-Cells in the Treatment of CD38 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
The pilot study evaluates CD38-targeted CAR T-cell therapy for relapsed or refractory acute myeloid leukemia (AML), a significant unmet medical need in hematological malignancies. The study's single-center design and open-label nature may limit generalizability but allows for focused data collection. The target population of CD38 positive AML patients presents a niche market opportunity, particularly as existing therapies may not effectively address relapsed cases. Competitive landscape analysis indicates a growing interest in CAR T-cell therapies, with several companies pursuing similar targets. Successful outcomes could position the sponsor favorably for partnerships or licensing agreements, enhancing their portfolio in immuno-oncology.
Indication: Acute Myeloid Leukemia
Modality: protein therapy
Target: CD38
Sponsor: The First Affiliated Hospital of Soochow University
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 17, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD38
View original source fields
Condition raw: Acute Myeloid Leukemia
Condition normalized: Acute Myeloid Leukemia
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: CD38
Target normalized: CD38